Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EMMS
2701
DELISTED
Emmis Communications Corp
EMMS
| $631K | ﹤0.01% |
234,081
-23,168
| -9% | -$63.2K |
|
2702
DLH Holdings
DLHC
$67.8M
| $627K | ﹤0.01% |
116,290
-3,850
| -3% | -$19.9K |
|
2703
Badger Meter
BMI
$3.91B
| $626K | ﹤0.01% |
15,700
-10,800
| -41% | -$419K |
|
|
DQ
2704
Daqo New Energy
DQ
$988M
| $625K | ﹤0.01% |
+150,500
| New | +$612K |
|
2705
PDS Biotechnology
PDSB
$13M
| $624K | ﹤0.01% |
3,040
+1,410
| +87% | +$278K |
|
|
BCOM
2706
DELISTED
B Communications Ltd
BCOM
| $624K | ﹤0.01% |
36,300
+1,300
| +4% | +$25.7K |
|
2707
American Eagle Outfitters
AEO
$2.72B
| $623K | ﹤0.01% |
+51,700
| New | +$649K |
|
|
LUB
2708
DELISTED
Luby's Inc.
LUB
| $620K | ﹤0.01% |
220,500
+41,300
| +23% | +$121K |
|
2709
Alto Ingredients
ALTO
$315M
| $619K | ﹤0.01% |
+99,082
| New | +$643K |
|
|
ICPT
2710
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $617K | ﹤0.01% |
+5,100
| New | +$591K |
|
|
TULP
2711
Bloomia Holdings
TULP
$17.2M
| $613K | ﹤0.01% |
85,557
+714
| +0.8% | +$5.51K |
|
|
TUES
2712
DELISTED
Tuesday Morning Corp
TUES
| $612K | ﹤0.01% |
+322,300
| New | +$787K |
|
2713
Teekay Tankers
TNK
$2.81B
| $611K | ﹤0.01% |
+40,651
| New | +$629K |
|
2714
NanoViricides
NNVC
$34.9M
| $610K | ﹤0.01% |
22,580
+2,170
| +11% | +$53.6K |
|
2715
FreightCar America
RAIL
$243M
| $609K | ﹤0.01% |
+35,000
| New | +$545K |
|
2716
Arrowhead Research
ARWR
$12.3B
| $606K | ﹤0.01% |
+374,164
| New | +$606K |
|
|
CIVI
2717
DELISTED
Civitas Solutions, Inc.
CIVI
| $602K | ﹤0.01% |
34,400
-9,300
| -21% | -$161K |
|
|
CGRN
2718
DELISTED
Capstone Green Energy Corporation Common Stock
CGRN
| $600K | ﹤0.01% |
88,191
+5,640
| +7% | +$39.7K |
|
|
STRR
2719
Star Equity Holdings
STRR
$40.1M
| $597K | ﹤0.01% |
44,530
+2,510
| +6% | +$34.3K |
|
|
VSR
2720
DELISTED
Versar, Inc.
VSR
| $591K | ﹤0.01% |
396,400
+15,900
| +4% | +$22.5K |
|
2721
Alphatec Holdings
ATEC
$1.49B
| $587K | ﹤0.01% |
317,187
+16,200
| +5% | +$32.7K |
|
2722
ImmuCell
ICCC
$99.3M
| $586K | ﹤0.01% |
79,900
+2,800
| +4% | +$16.6K |
|
|
PVLA
2723
Palvella Therapeutics
PVLA
$2.23B
| $586K | ﹤0.01% |
1,449
-1,731
| -54% | -$506K |
|
2724
Edgewell Personal Care
EPC
$1.32B
| $585K | ﹤0.01% |
7,700
-109,200
| -93% | -$8.03M |
|
|
DDE
2725
DELISTED
Dover Downs Gaming & Entertain
DDE
| $578K | ﹤0.01% |
521,100
+67,800
| +15% | +$74.2K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.